Influence of Pregnancy-Related Conditions on Human Epididymis Protein 4 Serum Levels in Comparison to CA 125 – a Prospective Cohort Trial

Auswirkungen von schwangerschaftsbedingten Erkrankungen auf den humanen Epididymis-Protein-4-Spiegel im Blut verglichen mit CA 125 – eine prospektive Kohortenstudie

Authors
Samira Abdel Azim1, Irene Mutz-Dehbalaie1, Verena Wieser1, Astrid Berger1, Bettina Böttcher2, Heidi Fiegl3, Christian Marth1, Andreas Widschwendter1

Affiliations
1 Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
2 Department of Gynecological Endocrinology and Reproductive Medicine, Medical University of Innsbruck, Innsbruck, Austria
3 Department of Gynecology and Obstetrics, Laboratory for Clinical Biochemistry, Medical University of Innsbruck, Innsbruck, Austria

Key words
HE4, CA 125, pregnancy, tumor marker, biomarker, adnexal mass

Schlüsselwörter
HE4, CA 125, Schwangerschaft, Tumormarker, Biomarker, Adnextumor

ABSTRACT

Introduction
HE4 and CA 125, two established biomarkers for assessing adnexal masses in non-pregnant women, are hardly investigated in pregnancy, especially in pregnancy-associated conditions. The aim was to evaluate HE4 and CA 125 levels in the course of pregnancy and to assess the impact of pregnancy disorders, contractions and rupture of membranes on HE4 and CA 125 serum levels in order to use these parameters for evaluation of adnexal masses in pregnancy.

Patients and Methods
Blood samples (n = 238) of 201 women seen at the Medical University of Innsbruck, Austria, were prospectively obtained during pregnancy and postpartum. Serum concentrations of HE4 and CA 125 were analyzed.

Results
HE4 serum levels were highest in the third trimester. Contractions (p < 0.001), rupture of membranes (p = 0.005) and pregnancy-associated diseases (p = 0.003) were associated with higher HE4 levels. As much as 97.5% of HE4 measurements remained below the recommended cut-off for premenopausal women (70 pmol/l). CA 125 levels were not altered by pregnancy-associated conditions. Generally, CA 125 exhibited a wider serum level variability, exceeding the established cut-off of 35 U/ml in 16.4%.

Supplementary material is available under https://doi.org/10.1055/a-1475-4296

Correspondence
Irene Mutz-Dehbalaie, MD
Department of Obstetrics and Gynecology, Medical University of Innsbruck
Anichstrasse 35, 6020 Innsbruck, Austria
irene.mutz-dehbalaie@i-med.ac.at

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

© 2021. The author(s).
Conclusions HE4 serum levels are influenced by several pregnancy-related conditions leading to significantly higher levels in these cases. Despite differing medians according to trimester, the 95th percentile cut-offs and almost all maximum values during the entire course of pregnancy were below the established cut-off for premenopausal women. It was also superior to the performance of ROMA index. Therefore, HE4 can be used as a valuable negative predictive marker for the assessment of adnexal masses during pregnancy.

Introduction Adnexal masses in pregnancy are a rare finding but present a challenge for physicians regarding clinical approach and management. They are usually discovered as an incidental finding during antenatal ultrasound screening. According to literature, adnexal masses are often assessed to distinguish between benign and malignant conditions. CA 125 (Cancer Antigen 125) is the gold standard biomarker for epithelial ovarian cancer and plays an important role, not only in diagnostic but also in prognostic assessment and therapy monitoring [6, 7]. Data on the effect of pregnancy on CA 125 levels are conflicting. Several studies have shown elevated marker concentrations at least at some point in pregnancy [8], thereby giving rise to the assumption that CA 125 is of limited diagnostic use in pregnancy. Other biomarkers, such as alpha-feto protein or β-hCG (human chorionic gonadotropin), that are routinely used to stratify germ cell malignancies are of limited value as pregnancy itself may influence levels [3].

Human epididymis protein 4 (HE4), has recently emerged as a new diagnostic and prognostic marker in ovarian and endometrial cancer [9, 10]. HE4 exhibits good sensitivity and superior specificity compared to CA 125. This was especially observed in pre-menopausal women, and it is less elevated in women with benign diseases [11].

ROMA (risk of Ovarian malignancy algorithm) is an index that combines the quantitative values of HE4, CA 125 and menopausal state in an algorithm to assess the risk for ovarian cancer. It was initially developed to improve the prediction compared to either marker alone [12].

Seven studies have investigated HE4 serum levels in pregnant women [13–19]. All of these studies only investigated healthy pregnant women, one group additionally looked at HE4 serum levels in cases of threatened first trimester miscarriage [16] and another investigated the ROMA index [15]. The results of these studies are partly conflicting as some authors report no difference in HE4 levels in pregnancy [17] or even lower levels than in pre-menopausal women [13] whereas others confirmed higher HE4 levels with advancing gestation [16, 19]. To date, no studies have been published to evaluate interferences of HE4 and CA 125 levels with regard to pregnancy-related conditions and postpartum.

The aim of this study was to evaluate HE4 serum levels in comparison to CA 125 levels in serum samples collected prospectively during pregnancy and after delivery. We also investigated the effect of contractions, rupture of membranes, pregnancy-associated diseases and delivery on HE4 serum levels. Additionally, we analyzed the performance of ROMA index compared to individual marker values alone.
Material and Methods

Study population
Blood samples (n = 238) were prospectively collected from a convenient cohort of 201 pregnant women, who presented at the Department of Obstetrics and Gynecology, Medical University of Innsbruck as part of routine prenatal care. The study was approved by the Ethics Committee of the Medical University of Innsbruck (reference number AN 4102; 292/417). Informed written consent was obtained from each woman included in this study. Exclusion criteria were age under 18 years, a history of cancer and active cancer.

We have used the three trimesters as defined timepoints for biomarker measurements. Trimesters were defined as first trimester (weeks 0–14), second trimester (weeks 15–26) and third trimester (from 27 weeks until delivery). Serum samples were obtained from 4 to 42 weeks of gestation and within three hours after delivery. In 20 out of 201 women two serum samples were available and in eight patients three or more serum samples were obtained. Ten serum samples were taken within three hours postpartum. Patient characteristics of the study population are depicted in Table 1.

Of all participating women 33 (16.4%) presented with contractions (i.e. preterm labor) or onset of labor and 27 (13.4%) with rupture of membranes at the time of blood sampling.

Observed pregnancy-associated conditions were diabetes (n = 8, 4.0%), hypertension (n = 8, 4.0%), HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) (n = 3, 1.5%), pre-eclampsia (n = 5, 2.5%) and fetal pathologies comprising hydrops (n = 8, 4.0%) and trisomy (n = 4, 2.0%).

We divided our study population into two subgroups: In order to obtain normal values for HE4 and CA 125 a subgroup of 125 women with neither pregnancy-associated conditions, fetal abnormalities, rupture of membranes nor contractions was formed, referred to as subgroup 1.

Subgroup 2 contained all women with rupture of membranes or contractions and included all cases of pregnancy-associated pathologies and eight cases of hydrops/trisomy.

Serum assays
Blood samples were taken during antenatal care visits. Serum was stored at −50°C until analysis. Specimens were analyzed by means of chemiluminescent microparticle immunoassays specific for CA 125 (ARCHITECT CA 125 II assay) or for HE4 (ARCHITECT HE4 assay; both Abbott GmbH, Wiesbaden, Germany) using the ARCHITECT i2000SR Immunoassay Analyzer [11].

ROMA index
ROMA index was determined by the logistic regression formula for premenopausal patients with the measured CA 125 and HE4 levels in the following algorithm: First the predictive index was calcu-

Table 1 Patient characteristics.

<table>
<thead>
<tr>
<th>Variable</th>
<th>All women (n = 201)</th>
<th>Subgroup 1 (n = 125)</th>
<th>Subgroup 2 (n = 76)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median</td>
<td>Range</td>
<td>Median</td>
</tr>
<tr>
<td>Age</td>
<td>30.9</td>
<td>18.3–44.8</td>
<td>30.8</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>25.7</td>
<td>16–45</td>
<td>24.9</td>
</tr>
<tr>
<td>HE4 (pmol/l)</td>
<td>36</td>
<td>17–144</td>
<td>31</td>
</tr>
<tr>
<td>CA 125 (U/ml)</td>
<td>22</td>
<td>3–524</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>n %</td>
<td>n %</td>
<td>n %</td>
</tr>
<tr>
<td>1st trimester</td>
<td>56</td>
<td>27.9</td>
<td>49</td>
</tr>
<tr>
<td>2nd trimester</td>
<td>19</td>
<td>9.5</td>
<td>17</td>
</tr>
<tr>
<td>3rd trimester</td>
<td>126</td>
<td>62.7</td>
<td>59</td>
</tr>
<tr>
<td>Twin pregnancy</td>
<td>13 *</td>
<td>6.5</td>
<td>10 *</td>
</tr>
<tr>
<td>Diabetes</td>
<td>8</td>
<td>4.0</td>
<td>8</td>
</tr>
<tr>
<td>Hypertension</td>
<td>8</td>
<td>4.0</td>
<td>8</td>
</tr>
<tr>
<td>HELLP</td>
<td>3</td>
<td>1.5</td>
<td>3</td>
</tr>
<tr>
<td>Pre-eclampsia</td>
<td>5</td>
<td>2.5</td>
<td>5</td>
</tr>
<tr>
<td>Hydrops</td>
<td>8</td>
<td>4.0</td>
<td>8</td>
</tr>
<tr>
<td>Trisomy</td>
<td>4</td>
<td>2.0</td>
<td>4</td>
</tr>
<tr>
<td>Contractions</td>
<td>33</td>
<td>16.4</td>
<td>33</td>
</tr>
<tr>
<td>Rupture of membranes</td>
<td>27</td>
<td>13.4</td>
<td>27</td>
</tr>
</tbody>
</table>

HELLP: hemolysis, elevated liver enzymes, low platelets.
Subgroup 1: All healthy women without rupture of membranes or contractions.
Subgroup 2: Women with rupture of membranes or contractions, pregnancy-associated diseases and/or fetal anomalies.
* Twin pregnancies are included within numbers of respective trimesters listed above.
lated by: $-12 + 2.38 \times \ln (\text{HE4}) + 0.0626 \times \ln (\text{CA 125})$. Then the predicted probability (ROMA index) was computed as follows: \[
\text{ROMA value} (\%) = \frac{e^{Pt}}{1+e^{Pt}} \times 100 \quad [12].
\]
ROMA values $< 7.4\%$ or $\geq 7.4\%$ were used to discriminate low risk and high risk results for premenopausal women [20].

Statistics
Differences between marker concentrations according to variables were tested with the Mann-Whitney U test and the Kruskal-Wallis test. A probability of $< 0.05$ was considered statistically significant. These statistical calculations were performed, and all figures created with SPSS, version 25.0.

Results
HE4 and CA 125 levels over the course of pregnancy
Distribution of HE4 according to trimesters was significantly different ($p < 0.001$) in all women ($n = 201$) and also in the group without pathologies or ruptured membranes/contractions ($n = 125$). HE4 levels rose significantly when measured longitudinally. Levels in the third trimester were significantly higher than in the first and second trimester (trimester 1 vs. 3 and trimester 2 vs. 3: $p < 0.001$; ➤Fig. 1a). In contrast CA 125 levels showed no differences in distribution throughout gestation (➤Fig. 1b).

Blood was drawn twice during pregnancy from 20 (10.0%) pregnant women, three times from eight women. The median time between the first and second and the first and third sampling was four and three weeks, respectively. Of the 238 blood samples ten were taken postpartum. Compared with sera of all pregnant women, considerably higher HE4 as well as CA 125 levels were noted after delivery (HE4, $p < 0.001$; CA 125, $p < 0.001$).

Range of marker levels
Median HE4 serum levels of all samples were 36 pmol/l (range 17–114 pmol/l), and median CA 125 levels were 22 U/ml (range 3–524 U/ml). ROMA index performance was satisfactory in the 1st and 2nd trimester but showed a higher proportion of high-risk results in the 3rd trimester (➤Table 2). First and third trimester values at the 95th percentile for HE4 were 43 and 61 pmol/l and for CA 125 values were 47 and 45 U/ml, respectively. Five serum samples (2.5%) exceeded the HE4 cut-off (> 70 pmol/l), and 33 samples (16.4%) exceeded the CA 125 cut-off (> 35 U/ml) as demonstrated in ➤Fig. 2.

➤Table 2 Median HE4 and CA 125 levels and ROMA Index according to trimesters.

<table>
<thead>
<tr>
<th>Variable</th>
<th>HE4 (pmol/l)</th>
<th>CA 125 (U/ml)</th>
<th>ROMA Index</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median</td>
<td>Range</td>
<td>Median</td>
</tr>
<tr>
<td>All samples</td>
<td>36</td>
<td>17–114</td>
<td>22</td>
</tr>
<tr>
<td>1st trimester</td>
<td>28</td>
<td>17–51</td>
<td>19.5</td>
</tr>
<tr>
<td>2nd trimester</td>
<td>29</td>
<td>21–37</td>
<td>21</td>
</tr>
<tr>
<td>3rd trimester</td>
<td>41</td>
<td>20–114</td>
<td>24</td>
</tr>
</tbody>
</table>

➤Fig. 1 Serum levels of HE4 (a) and CA 125 (b) by trimester for all samples.
Analyses in subgroups

In subgroup 1 (which included all healthy pregnant women, i.e. women without rupture of membranes, contractions, pregnancy-associated pathologies or cases of hydrops/trisomy) the median value for HE4 was 31 pmol/l (range 17–76 pmol/l) at a 95th percentile of 51 pmol/l and the median value for CA 125 was 21 U/ml (range 5–180 U/ml) with a 95th percentile of 46 U/ml.

Age was divided into three categories (18–29, 30–39, ≥ 40) and was not associated with differences between HE4 and CA 125 levels. Importantly, women with twin pregnancies (n = 13, 6.5%) showed no differences in HE4 or CA 125 marker levels compared to women with singleton pregnancies (HE4 p = 0.499; CA 125 p = 0.442). Median HE4 was 35 pmol/l (range 23–67) and median CA 125 level was 20 U/ml (range 10–101). We therefore included uneventful twin pregnancies (n = 10) in subgroup 1 and those with a pathologic condition (n = 3) (i.e. hypertension, hydrops) in subgroup 2.

Thirty-three (16.4%) samples were obtained from women with contractions, eight women presented in labor and 27 samples (13.4%) were obtained from women after spontaneous rupture of membranes (SROM). HE4 serum levels in these women were markedly higher (p < 0.001) than levels in healthy pregnant wom-
en (subgroup 1). However, no difference was seen in CA 125 levels among these women (▶ Fig. 3a and b).

When assessing only sera of women in the third trimester (n = 126) HE4 levels remained significantly elevated in women with ruptured membranes or contractions as compared to CA 125 (p < 0.001 vs. p = 0.145), see supplemental Fig. S1.

HE4 levels were higher in sera of women with pregnancy-associated conditions than in healthy pregnant women (n = 125) (p = 0.037). When dichotomizing women with pathologies like hypertension, HELLP, preeclampsia and diabetes (n = 23; 11.4%) and those with hydrops and/or chromosomal anomaly (n = 9; 4.7%), the effect persisted only in the first group (p = 0.003) (▶ Fig. 4a).

However, CA 125 levels did not differ when comparing the two pathology groups and healthy pregnant women (▶ Fig. 4b).

Discussion

Although HE4 plays a potent role in the discrimination of adnexal masses, data concerning its reliability in pregnancy are limited. Seven studies with a combined total of 1504 women reported on HE4 levels in pregnancy [13–19]. Except for one group [16], who investigated the effect of threatened miscarriage on HE4 levels, none of the studies took into account interference of serum HE4 levels and any particular pregnancy-associated conditions. Lu et al. [15] additionally evaluated ROMA index in pregnancy.

To our knowledge, this is the first study on the effect of pregnancy-associated conditions on HE4 and CA 125 serum levels.

In premenopausal women, where CA 125 is of limited value in detecting ovarian cancer due to its low specificity, HE4 is especially appreciated [11, 21]. HE4 exhibits the most compelling benefit in early stages of ovarian cancer with higher sensitivity in comparison to CA 125 [22].

In our study CA 125 median values showed no difference when comparing the individual trimesters (▶ Fig. 1). However, despite stable median values, our data demonstrate rather wide ranges of CA 125 (▶ Table 1).

A review of tumor markers in pregnancy including ten publications [8] found elevated CA 125 levels in up to 35% of all measurements. Levels were predominately higher in the first trimester, decreasing to stable median values below the cut-off in the second and third trimester. This is in accordance with the data of the aforementioned studies. A possible reason for the discrepancy between higher first trimester levels reported by previous studies and our results might be that most of our first trimester specimens were collected at the time of first trimester screening at 12 to 13 weeks of gestation. At this point CA 125 levels may already be decreasing. In a study by Park et al. [14], CA 125 levels in the pregnant cohort did not exceed the established cut-off by reaching a maximum level of 30.7 U/ml, although they were more than 50% higher than those in the non-pregnant group.

Our data on HE4 distribution according to trimester show significantly higher median levels in the third compared to the first and second trimester (p < 0.001; ▶ Fig. 1). This was shown for each subgroup. Investigation of longitudinally collected sera of our population showed significantly higher levels with advancing gestational age. The results are in line with those of Lu et al. [15] who reported increasing median HE4 concentrations with each trimester. Moore et al. [13] identified no differences in median HE4 levels by trimester, but showed significant differences in the distribution of HE4 levels. According to trimesters our 95th percentile cut-offs reach from 43.8 to 61.0 pmol/l, and the 95th percentile cut-off for all included pregnant women in our study was 51 pmol/l. They do not markedly differ from those reported by Moore et al. (35.1 to 50.2 pmol/l and 49.6 pmol/l, respectively) [13]. It has to be mentioned that Moore et al. [11] and Park et al. [23] used the HE4 EIA kit by Fujirebio (Fujirebio Diagnostics Inc. Malvern, PA) with a 95th percentile cut-off for premenopausal women of 89.1 pmol/l. Ruggeri et al. have confirmed a similar per-
formance of the two assays [24]. Lu et al. determined HE4 by Elecsys HE4 Kit (Roche) with a cut-off of 65.8 pmol/l.

Park et al. [23] reported the 95th percentile cut-offs for HE4 of 29.7 to 30.3 pmol/l in healthy individuals. They did not determine cut-offs for pregnant women but mentioned that median levels were not higher than 7 pmol/l as compared to the non-pregnant population. It is noteworthy that in the population of Lu et al. [15] 23.3% of HE4 measurements in the third trimester were beyond the premenopausal cut-off level (for Chinese women) of 65.8 pmol/l.

In contrast to the above-mentioned studies, we evaluated HE4 distribution according to certain conditions related to pregnancy. Thirty-three (16.4%) of our specimens were obtained from women having contractions and during labor. HE4 serum levels in these women were markedly higher (p < 0.001), whereas no difference was seen in CA 125 levels (p = 0.053). Similarly, HE4 levels in samples obtained from women after rupture of membranes were significantly higher (p = 0.045), whereas CA 125 was not altered (p = 0.636) (Fig. 2). To avoid bias due to marker distribution according to trimester, analyses were performed only in women in the third trimester.

Pathologic conditions investigated in this study include hypertension, HELLP, preeclampsia and diabetes, as well as fetal hydrops and fetal trisomy. Marker levels according to pathologic findings were evaluated in subgroup 2.

Pregnancy-related diseases (hypertension, HELLP, preeclampsia and diabetes) were associated with significantly higher HE4 levels (p = 0.003) than levels in healthy pregnant women. In case of fetal hydrops and trisomy HE4 serum levels were not increased (Fig. 3 a). The underlying mechanism might be a decreased glomerular filtration rate (GFR), since all the above-mentioned conditions are accompanied by restricted renal function. GFR is known to be reduced by 30 to 40% in preeclampsia [25]. Hypertension and diabetes are not merely risk factors for (pre-) eclampsia but are also precursor states. Additionally, renal impairment is also a known factor in these conditions. Nagy et al. [26] described the impact of reduced GFR on renal HE4 clearance. Higher creatinine levels in patients with impaired renal function were shown to be associated with higher HE4 serum levels [27]. Compared with all sera of pregnant women, considerably higher HE4 as well as CA 125 levels were noted postpartum (HE4 p < 0.001, CA 125 p < 0.001); for CA 125 this has already been reported [28]. It remains unclear to what extent placental factors may contribute to these phenomena as well as to higher serum levels in labor and after rupture of membranes.

This study of HE4 levels in pregnancy is the first to evaluate serum levels throughout the course of pregnancy and to simultaneously assess potential interference from pregnancy-associated conditions. Unfortunately, only limited data were available on adnexal masses in our study population. Further studies are needed to address this issue. Another limitation of our study is the small number of longitudinal measurements, because only few women in our study attended full antenatal care at our institution. Contractions, rupture of membranes and the pregnancy-associated diseases as hypertension, HELLP, preeclampsia and diabetes were seen to be associated with significantly higher HE4 levels. CA 125 levels were not influenced by these conditions. Generally, CA 125 exhibited a wider range, exceeding the established cut-off of 35 U/ml in 33 samples (16.4%), whereas HE4 maximum values remained below the recommended cut-off for premenopausal women of 70 pmol/l, in 97.5% of cases.

ROMA index performance was satisfactory in the 1st and 2nd trimester but showed a higher proportion of high-risk results in the 3rd trimester. This fact can mainly be attributed to the great range of CA 125 especially towards the end of pregnancy. ROMA index performed better when only patients with the absence of pathological and pregnancy-related conditions were analyzed. In this group a high-risk result was only obtained in 6.4% of cases. Although ROMA index was initially introduced to improve the risk prediction compared to either marker alone, we could not confirm this result in our cohort of pregnant women. CA 125 was the least reliable factor followed by ROMA index. HE4 performance was superior to the latter to two. Our observations are in line with previously published data by Lu et al. [15]. They also found that ROMA index values in the third trimester are of smaller clinical significance, due to the wide range of CA 125.

Conclusion

Based on its stable levels HE4 appears to be a valuable and reliable biomarker for the diagnosis of adnexal masses in pregnancy. However, when HE4 serum levels are measured longitudinally throughout pregnancy to monitor adnexal masses, pregnancy-related changes in HE4 levels such as rupture of membranes, contractions and pregnancy-associated diseases must be taken into account. Cut-off values for HE4 in pregnancy should be implemented.

Funding

ARCHITECT CA 125 and HE4 assays were kindly provided by Abbott GmbH, Wiesbaden, Germany.

Ethical Standards

The study was approved by the Ethics Committee of the Medical University of Innsbruck (reference number AN 4102; 292/417) and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed written consent was obtained from each woman included in this study.

Acknowledgements

We would like to acknowledge Andrea Sapinsky for her administrative support.

Conflict of Interest

The authors declare that they have no conflict of interest.
References


[6] Chan KKL, Chen C


[10] Dakubo GD. Cancer Biomarkers in Body Fluids. Cham: Springer International Publishing; 2017


[20] Dakubo GD. Cancer Biomarkers in Body Fluids. Cham: Springer International Publishing; 2017


